To evaluate the therapeutic efficacy of NCAM1 mAb on tauopathy development in vivo, we utilized the human MAPTP301S transgenic mice (PS19 line), a well-established model for tauopathy24 and exhibits increased FFA18:2 levels in the brain compared to wild type (WT) mice25. The gene discussed is NCAM1; the disease is tauopathy.